BioVaxys Technology Corp.

08:54 AM EST - BioVaxys Technology Corp. : Announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the Company's SARS-CoV-2 vaccine. David Berd , MD, Chief Medical Officer of Biovaxys, explained that "Biovaxys will compare the binding of haptenized spike protein with the non-haptenized. The results could provide evidence that our vaccine has lowered potential for some of the observed serious vaccine side effects." BioVaxys Technology Corp. shares C.BIOV are trading unchanged at $0.50.

Stocks in Play